Supriya Lifescience Limited
Aditya Birla Sun Life Insurance decreased its stake in Supriya Lifescience Limited from 2.19% to 2.16% by selling 20,826 shares.
A pharmaceutical manufacturer engaged in the production of active pharmaceutical ingredients across diverse therapeutic segments including antihistamine, analgesic, anaesthetic, vitamin, anti-asthmatic, and anti-allergic formulations. The company operates integrated manufacturing facilities focused on API synthesis and development for both domestic and international markets. Supriya Lifescience maintains a broad product portfolio serving multiple therapeutic areas within the pharmaceutical industry.
Joint venture between Aditya Birla Capital and Sun Life Financial of Canada. Total AUM of Rs 99,496 crore as of March 2025. CIO Devendra Singhvi runs a diversified equity book across ULIP, participating and group funds with a multi-cap bias. Active in primary issuances and secondary market block deals across sectors.